La catena delle opzioni mostra i dati chiave delle opzioni azionarie di N2OFF a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per N2OFF..

N2OFF (NASDAQ:NITO) Azioni, Catena delle Opzioni

N2OFF

N2OFF Inc is a pioneering agri-food tech company dedicated to developing sustainable solutions for the plant-based food industry. Operating through two subsidiaries, it delivers integrated solutions for enhanced safety, quality, and sustainability from field to fork.

N2OFF Inc

NITORI HOLDINGS CO LTD by Nitori Holdings Co., Ltd.

Nitori Holdings Co Ltd

NITORI HOLDINGS CO U/ADR by Nitori Holdings Co., Ltd.

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.85%. Currently, Gilead Sciences has a market capitalization of $113.70 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a price of $91.23 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736201708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

GILD

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

A Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) analyst sees upcoming revamped and new vehicle models helping to boost sales along with Full Self-Driving licensing potential, brushing aside the company's recent<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on"> fourth-quarter delivery miss.</a>
The Tesla Analyst: Tesla analyst Stephen Gengaro reiterated a Buy rating on Tesla. He also raised the price target from $441 to $492.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41501607/tesla-q3-earnings-highlights-eps-beat-revenue-miss-shares-climb-on-2025-timeline-for-lower-cost-evs">Tesla Q3 Earnings Highlights: EPS Beat, Revenue Miss, Shares Climb On 2025 Timeline For Lower-Cost EVs</a>
The Analyst Takeaways: The upcoming rollout of the "Model 2" from Tesla is a catalyst, Gengaro said in a new investor note.
Strong demand is anticipated for the lower-priced Model 2, according to the analyst. The introduction of this new vehicle could serve as a new way for Tesla vehicles to be more accessible to a wider range of consumers.
The analyst also highlighted the company's revamped Model 3 and a Model Y refresh as items that could boost vehicle sales, as <a href="https://in.investing.com/news/analyst-ratings/stifel-lifts-tesla-stock-target-buy-rating-on-growth-outlook-93CH-4598738">reported </a>by Investing.com.
"We believe Tesla is very well positioned to deliver robust multi-year growth in 2025-27+," Gengaro said in the note, as <a href="https://x.com/SawyerMerritt/status/1876294513138012509">shared </a>by Sawyer Merritt.
The analyst considers the potential removal of $7,500 in electric vehicle tax credits under the new White House administration as an advantage for Tesla over competitors.
Outside of vehicle sales, the analyst also highlights Tesla's Full Self-Driving and artificial intelligence initiatives that could bring value and revenue to the company and its shares.
"We also believe Tesla's AI-based Full Self-Driving initiative has the potential to generate significant value through both sales of FSD, possible licensing agreements, and a critical part of longer-term Cybercab initiatives."
The analyst's price target increase comes after the delivery miss and the company posting its first annual sales decline on a year-over-year basis. Analysts <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42777950/teslas-first-sales-drop-splits-wall-street-2025-will-be-the-prove-it-year">continue to debate</a> what the short-term and long-term looks like for the electric vehicle leader with new vehicles, robotaxis and FSD among the most covered topics.
Tesla will report fourth-quarter financial results after the market closes on Jan. 29. 
Price Action: Tesla stock was up 0.2% to $411.05 on Monday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 71% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42772702/tesla-analyst-says-fsd-test-drive-shows-imperfections-not-ready-for-prime-time-yet">Tesla Analyst Says FSD Test Drive Shows Imperfections, &#8216;Not Ready For Prime Time Yet&#8217;</a></li>
</ul>
Image via Tesla

Analyst Color

Price Target

Reiteration

Analyst Ratings

TSLA

Tesla Stock 'Well Positioned To Deliver Robust Multi-Year Growth': Why Analyst Is Raising Price Target After Deliveries Miss

New York City&#8217;s congestion toll program launched on Sunday, adding new fees for drivers and rideshare customers. Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and LYFT, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) lobbied in favor of congestion tolls and are positioned to benefit<a href="https://www.benzinga.com/news/global/25/01/42806918/new-york-citys-historic-congestion-pricing-starts-sunday-uber-and-lyft-passengers-to-pay-for-entering-manhattan"> from the new fees. </a>
What To Know: The new congestion toll program is intended to reduce traffic congestion, improve air quality and raise funds for the city's mass transit system. Most drivers entering Manhattan&#8217;s Congestion Relief Zone, south of 60th Street, will be charged a $9 toll during peak hours while rideshare services will be charged significantly less $1.50 per vehicle. 
Read Next: <a href="https://www.benzinga.com/25/01/42821300/biden-set-to-ban-future-offshore-oil-drilling-4-stocks-to-watch">Biden Set To Ban Future Offshore Oil Drilling: 4 Stocks, 2 ETFs To Watch</a>
According to <a href="https://nypost.com/2025/01/04/us-news/uber-lyft-spent-millions-pushing-for-nyc-congestion-pricing-and-stand-to-make-killing/">a report </a>from the New York Post, Uber and Lyft have spent millions of dollars lobbying in favor of the congestion toll program and stand to benefit from its rollout.
According to the New York Post report, Lyft contributed $18,500 in each of the last four years to Gov. Kathy Hochul's campaign, which championed the new congestion tolls. The Post also reported that Uber spent $2 million between 2015 and 2019 to promote congestion tolls. 
Why It Matters: Uber and Lyft are passing the additional fee to the customer so the increased tolls will not directly affect the companies' bottom lines. The companies could also benefit from reduced traffic leading to faster service and from drivers switching to ridesharing services in order to avoid higher tolls.&nbsp;
Lyft announced it is refunding the new $1.50 congestion fee in the form of a credit for future trips for all rides completed in the month of January.&nbsp;
"Since 2019 rideshare riders have already paid a $2.75 congestion fee to the MTA for rides that start, end or pass through a separate congestion zone that begins below 96th Street in Manhattan. We don't think riders should be double taxed, and we lobbied hard for them to be exempt from this new additional $1.50 congestion fee," the company said in <a href="https://www.lyft.com/blog/posts/navigating-the-new-nyc-congestion-fee-with-lyft">a statement</a> released last week.&nbsp;
Josh Gold, a Uber spokesman, told the New York Post that the company was "early supporters of congestion pricing" but "government can't continue to raise prices and fees on New Yorkers and expect no consequences."
The full impact of congestion tolling on the rideshare services will become clearer as future ridership figures come in.&nbsp;
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a></li>
</ul>
Photo: Shutterstock

Travel

Legal

Movers

General

LYFT

UBER

Uber, Lyft Could Gain From New York City Congestion Pricing They Championed

Offerings

AerCap Prices Offering Of Senior Notes, Consisting Of $750M Of 4.875% Senior Notes Due 2028 And $750 Million Of ' 5.375% Senior Notes Due 2031

Every January, traders and market enthusiasts look to the first month's performance as a potential crystal ball <a href="https://www.benzinga.com/analyst-ratings/analyst-color">for the year ahead. </a>
The &#8216;January Barometer&#8217; and the &#8216;January Effect&#8217;—two staples of market lore—suggest that January holds predictive power over the entire year's stock market trajectory. 
But while these ideas are catchy, investors may find more reliable gains by focusing elsewhere.
<h3 class="wp-block-heading">The January Effect And Barometer: A Closer Look</h3>
The January Effect refers to a historical trend where stocks tend to rise during the month of January. This phenomenon is often attributed to year-end tax-loss harvesting, where investors sell off losing positions in December to offset capital gains, only to reinvest at the start of the new year.
Meanwhile, the January Barometer, introduced by Yale Hirsch in 1972, takes a broader perspective. It suggests that the S&amp;P 500's performance in January can serve as a predictor for the rest of the year. 
The logic behind the January Barometer is simple, with the sentence "as goes January, so goes the year," frequently cited in financial circles. 
According to Ed Yardeni, president of Yardeni Research, the January Barometer has proven accurate more often than not.
Data shows that between 1965 and 2024, January's performance matched the market's full-year direction in 42 out of 59 years, or about 71% of the time. 
Moreover, January ranks as the fourth-best performing month for stocks historically, with an average gain of 1.2% since 1928.
Looking at a more recent history, in 2024, the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), posted a 1.6% gain in January and ended the year up by a strong 23.3%. In 2023, a spectacular 6.3% surge in January set the stage for a 24.4% annual rally, while in 2022, a sharp 6.3% drop in January foreshadowed a nearly 20% decline for the year.
On paper, these stats make January look significant. But are they truly actionable?
<h3 class="wp-block-heading">Flaws In January's Predictive Power</h3>
While intriguing, the January Barometer and Effect often rely on loose correlations rather than causal relationships.
Almost all months of the year, with the sole exclusion of September, tend to show historical gains simply because stock prices have a natural upward trend over time. 
The January Effect, tied to tax-loss selling and reinvestment, also presents logical inconsistencies, as Yardeni highlighted.
If tax-loss selling depresses December's performance, how does December maintain its reputation for the so-called Santa Claus rallies? In fact, December outperforms January historically, with an average gain of 1.3% since 1928, making it the third-best month for stocks.
These contradictions highlight why traders should be cautious when relying on January-based strategies. Statistical quirks don't necessarily translate into consistent profits.
<h3 class="wp-block-heading">Look Beyond January</h3>
January's allure as a market bellwether often overshadows its true significance. Although the January Barometer and Effect have historical appeal, their predictive power is more coincidence than strategy.
&#8220;It is better simply to stay invested for the long run than to trade these two January statistical regularities,&#8221; Yardeni said.
While the January Barometer and Effect have historical merit, their predictive power pales in comparison to the benefits of long-term, fundamentals-based strategies. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42825901/this-key-bond-market-gauge-predicted-major-wall-street-crashes-is-50-drop-looming-in-2025">This Key Bond Market Gauge Predicted Major Wall Street Crashes: Is 50% Drop Looming In 2025?</a></li>
</ul>
Image created by Tara Anand for Investopedia

Broad U.S. Equity ETFs

Psychology

ETFs

'As Goes January, So Goes The Year' - Here's Why Investors Should Focus Elsewhere

Across the recent three months, 22 analysts have shared their insights on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $32.45, a high estimate of $40.00, and a low estimate of $25.00. This current average has increased by 7.66% from the previous average price target of $30.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200844_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Confluent's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Confluent. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Confluent compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Confluent's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Confluent's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Confluent analyst ratings.</a>
<h2>About Confluent</h2>
Confluent Inc is a new category of data infrastructure designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. Its products include Confluent Platform; Connectors; ksqlDB and others. The company generates revenue from the sale of subscriptions and services. Geographically, it derives a majority of its revenue from the United States. The company provides solutions to Financial Services; Insurance; Retail and eCommerce; Automotive; Government and other sectors.
<h3>A Deep Dive into Confluent's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Confluent's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 24.99%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Confluent's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -29.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Confluent's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.2%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Confluent's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Confluent's debt-to-equity ratio stands notably higher than the industry average, reaching 1.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CFLT

What Analysts Are Saying About Confluent Stock

Ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) were provided by 14 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by a high estimate of $82.00 and a low estimate of $58.00. This current average has decreased by 0.93% from the previous average price target of $68.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200837_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of CVS Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$67.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CVS Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of CVS Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CVS Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVS Health analyst ratings.</a>
<h2>About CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Breaking Down CVS Health's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.31% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CVS Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): CVS Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: CVS Health's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down CVS Health: 14 Analysts Share Their Views

10 analysts have expressed a variety of opinions on Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $175.3, a high estimate of $185.00, and a low estimate of $165.00. This current average has increased by 9.26% from the previous average price target of $160.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200831_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Quest Diagnostics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$182.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$168.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$157.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Quest Diagnostics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Quest Diagnostics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Quest Diagnostics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Get to Know Quest Diagnostics Better</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
<h3>Quest Diagnostics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Quest Diagnostics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 8.41%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.04%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Quest Diagnostics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.35%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Quest Diagnostics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Quest Diagnostics's Future

The Company intends to use the net proceeds from the offering for [general corporate purposes, capital expenditures, working capital and general and administrative expenses].
 &nbsp;

AMST

Amesite Intends To Offer And Sell Shares Of Its Common Stock (Or Pre-funded Warrants In Lieu Thereof) In Public Offering

13 analysts have shared their evaluations of Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $118.08, along with a high estimate of $136.00 and a low estimate of $100.00. This current average has increased by 1.46% from the previous average price target of $116.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200823_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Arch Capital Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Jay Cohen</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jay Cohen</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$126.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$134.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$107.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Arch Capital Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Arch Capital Group compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Arch Capital Group's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACGL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arch Capital Group analyst ratings.</a>
<h2>Discovering Arch Capital Group: A Closer Look</h2>
Arch Capital Group Ltd is a Bermuda company which writes insurance and reinsurance with operations in Bermuda, the United States, Canada, Europe, Australia and United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage two operating segments: corporate and other. The insurance segment provides specialty risk solutions to client across a variety of industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
<h3>Arch Capital Group's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Arch Capital Group displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 36.05%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Arch Capital Group's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.74% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Arch Capital Group's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Arch Capital Group's debt-to-equity ratio is below the industry average. With a ratio of 0.13, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACGL

Assessing Arch Capital Group: Insights From 13 Financial Analysts

During the last three months, 7 analysts shared their evaluations of Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $106.29, with a high estimate of $124.00 and a low estimate of $98.00. This current average reflects an increase of 4.38% from the previous average price target of $101.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200816_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Aflac is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$107.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$124.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$106.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Kligerman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$102.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Aflac. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Aflac compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Aflac's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Aflac's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AFL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Aflac analyst ratings.</a>
<h2>Unveiling the Story Behind Aflac</h2>
Aflac Inc offers supplemental health insurance and life insurance in United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling majority of its policies directly to consumers at their places of work and also reaches out to its customers out of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
<h3>Aflac: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Aflac faced challenges, resulting in a decline of approximately -39.69% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Aflac's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -3.06%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Aflac's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.37%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Aflac's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Aflac: Insights From 7 Financial Analysts

Acuity Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) has outperformed the market over the past 20 years by 4.21% on an annualized basis producing an average annual return of 12.66%. Currently, Acuity Brands has a market capitalization of $9.38 billion. 
Buying $1000 In AYI: If an investor had bought $1000 of AYI stock 20 years ago, it would be worth $10,731.33 today based on a price of $304.00 for AYI at the time of writing.
<h3>Acuity Brands's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736200812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Acuity Brands Stock In The Last 20 Years

Across the recent three months, 9 analysts have shared their insights on Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Upwork, revealing an average target of $19.0, a high estimate of $24.00, and a low estimate of $16.00. Observing a 24.84% increase, the current average has risen from the previous average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1736200809_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Upwork. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kunal Madhukar</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Marvin Fong</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Andrew Boone</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rohit Kulkarni</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Upwork. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Upwork compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Upwork's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Upwork's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UPWK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Upwork analyst ratings.</a>
<h2>All You Need to Know About Upwork</h2>
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
<h3>Key Indicators: Upwork's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Upwork's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.27%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Upwork's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.32%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.68%, the company showcases effective utilization of assets.
Debt Management: Upwork's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.9.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UPWK

Where Upwork Stands With Analysts

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares traded lower on Monday. The company unveiled <a href="https://www.benzinga.com/pressreleases/25/01/b42813839/intel-extends-leadership-in-ai-pcs-and-edge-computing-at-ces-2025">new AI PC processors at CES 2025</a>.
What Happened: Intel has unveiled a new suite of Intel&nbsp;Core&nbsp;Ultra (Series 2) processors aimed at revolutionizing mobile computing for businesses, creators and enthusiast gamers. Intel&#8217;s latest processors come packed with AI enhancements, increased efficiency and performance improvements.
&#8220;The strength of our AI PC product innovation, combined with the breadth and scale of our hardware and software ecosystem across all segments of the market, is empowering users with a better experience in the traditional ways we use PCs for productivity, creation and communication, while opening up completely new capabilities with over 400 AI features,&#8221; said Michelle Johnston Holthaus, interim co-CEO of Intel and CEO of Intel Products. 
&#8220;And Intel is only going to continue bolstering its AI PC product portfolio in 2025 and beyond as we sample our lead Intel 18A product to customers now ahead of volume production in the second half of 2025.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In 2024 — Where Do Tesla, Nvidia, GameStop, Trump Media Stocks Rank?</a>
Intel unveiled new Ultra 2000V series mobile processors for businesses, Core&nbsp;Ultra 200HX and H series mobile processors for AI acceleration, Core Ultra 200U series mobile processors for mobile users, a new Core Ultra 200S series desktop processor portfolio and processors for edge computing. The company also provided updates on its 18A manufacturing and next-generation processor family.
Intel noted that its partnership with Microsoft on Copilot+ PCs aims to continue to advance AI-driven innovation, enhanced security and superior performance into 2025.
Intel Core Ultra 200V series-powered systems with the Intel vPro platform are available at online and in-store retailers as of Monday. Intel Core Ultra 200H and U series-powered systems are expected to become available in February. Intel Core Ultra 200HX series-powered systems are expected to become available in the first half of 2025. Intel Core Ultra 200S series desktop processors and OEM systems will be available through online and in-store retailers beginning Jan. 13.
See Also: <a href="https://www.benzinga.com/25/01/42813592/ai-chip-stocks-nvidia-broadcom-amd-taiwan-semi-micron-super-micro-surge-on-monday-whats-going-on">AI Chip Stocks Nvidia, Broadcom, AMD, Taiwan Semi, Micron, Super Micro Surge Premarket: Whats Going On?</a>
INTC Price Action: <a href="http://benzinga.com/quote/intc">Intel shares</a> initially traded higher Monday morning before pulling back. The stock closed Monday down 3.36% at $19.87, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

INTC

What's Going On With Intel Stock Monday?

Congress gathered on Monday to certify <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">President-elect Donald Trump's election</a> victory under the tightest national security levels possible in a stark reminder of four years ago when the U.S. Capitol <a href="https://www.benzinga.com/government/21/01/19049660/washington-dc-descends-into-anarchy-as-trump-supporters-storm-us-capitol-delay-electoral-college-vot">descended into chaos and violence</a> on Jan. 6, 2021, when lawmakers gathered to certify then-President-elect Joe Biden's win.
<h2 class="wp-block-heading">Things Are Different This Jan. 6: &#8216;Democracy Prevails&#8217; </h2>
When Vice President Kamala Harris walked into the Senate chamber on Monday to undertake the traditional role of certifying the national election, she issued a simple declaration when asked about the procedure by NBC News. "Democracy prevails," she said. 
Harris oversaw the process as four senators confirmed each state&#8217;s votes, which she lost to Trump, resulting in his return to the White House. Once the total vote reached a threshold, Harris certified Trump&#8217;s election victory.
&#8220;I do believe very strongly that America&#8217;s democracy is only as strong as our willingness to fight for it &#8230; Otherwise, it is very fragile, and it will not be able to withstand moments of crisis. And today, America&#8217;s democracy stood,&#8221; Harris said in comments after the count, <a href="https://abcnews.go.com/Politics/congress-meets-certify-trumps-2024-election-victory/story?id=117380065">reported</a> ABC News
NBC <a href="https://www.nbcnews.com/politics/kamala-harris/kamala-harris-approaching-certifying-election-loss-trump-rcna186298">reported</a> that Harris broke into a smile upon receiving a standing ovation from the Democratic party when her own vote total for the November election was read. The totals were 75,000,783 votes for Harris to Trump's 77,285,106.
<h2 class="wp-block-heading">Former VP Mike Pence Seemed Calmer This January 6</h2>
Trump&#8217;s former Vice President, Mike Pence, who faced <a href="https://www.cnn.com/videos/politics/2021/01/15/mike-pence-close-call-capitol-riot-foreman-vpx.cnn">threats </a>from rioters during the Jan. 6 attack on the Capitol—an event some allege <a href="https://www.benzinga.com/news/23/10/35528275/experts-testify-on-jan-6-in-trumps-14th-amendment-colorado-case-ex-president-expressed-messages-that">was incited by Trump</a>—sounded much calmer this year.
"The peaceful transfer of power is the hallmark of our democracy and today, members of both parties in the House and Senate along with the vice president certified the election of our new president and vice president without controversy or objection," he <a href="https://x.com/Mike_Pence/status/1876340275037266113">said</a> in on X.  
In the days and weeks after the Jan. 6 Capitol riot, seven people, including three law enforcement officers, lost their lives, according to a <a href="https://www.hsgac.senate.gov/imo/media/doc/HSGAC&amp;RulesFullReport_ExaminingU.S.CapitolAttack.pdf" target="_blank" rel="noreferrer noopener">bipartisan</a> Senate report. 
This Jan 6, 2025, the confirmation process went off without incident and was over in about 30 minutes.
Now read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42827796/maga-meme-coin-surges-20-boosting-donald-trumps-crypto-portfolio-11-9m">MAGA Meme Coin Surges 20%, Boosting Donald Trump&#8217;s Crypto Portfolio $11.9M</a></li>
</ul>
Photo: miss.cabul/Shutterstock.com

Government

Politics

Trump Confirmed President By VP Harris As Pence Hails 'Peaceful Transfer' This Jan. 6

Legendary investor Warren Buffett had a 2024 to remember with Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) reaching the $1 trillion market capitalization milestone for <a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig">the first time.</a>
During the year, Buffett&#8217;s Berkshire Hathaway also outperformed the S&amp;P 500, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>). 
Overall, Berkshire Hathaway stock was up 27.1% in 2024 versus a 24.1% gain for SPDR S&amp;P 500 ETF Trust, according to data from <a href="https://www.macrotrends.net/stocks/charts/BRK.B/berkshire-hathaway/stock-price-history">Macrotrends</a>. That&#8217;s despite Berkshire Hathaway offloading top-performing Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock<a href="https://www.benzinga.com/markets/equities/24/12/42666459/warren-buffett-once-called-berkshire-the-opposite-of-those-who-hurry-to-sell-now-hes-offloading-apple-and-snapping-up-occidental-petroleum-amid-a-20-drop"> during the year.</a>
Here's a look at the gains of Berkshire Hathaway B shares vs. the SPY over the last 20 <a href="https://www.macrotrends.net/stocks/charts/SPY/spdr-s-p-500-etf/stock-price-history">years</a>:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>YEAR</td>
<td>BRK-B</td>
<td>SPY</td>
<td>WINNER</td>
</tr>
<tr>
<td>2024</td>
<td>+27.1%</td>
<td>+24.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2023</td>
<td>+15.5%</td>
<td>+26.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2022</td>
<td>+3.3%</td>
<td>-17.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2021</td>
<td>+29.0%</td>
<td>+28.7%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2020</td>
<td>+2.4%</td>
<td>+18.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2019</td>
<td>+10.9%</td>
<td>+31.2%</td>
<td>SPY</td>
</tr>
<tr>
<td>2018</td>
<td>+3.0%</td>
<td>-4.6%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2017</td>
<td>+21.6%</td>
<td>+21.7%</td>
<td>SPY</td>
</tr>
<tr>
<td>2016</td>
<td>+23.4%</td>
<td>+12.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2015</td>
<td>-12.1%</td>
<td>+1.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2014</td>
<td>+26.6%</td>
<td>+13.5%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2013</td>
<td>+32.2%</td>
<td>+32.3%</td>
<td>SPY</td>
</tr>
<tr>
<td>2012</td>
<td>+17.6%</td>
<td>+16.0%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2011</td>
<td>-4.8%</td>
<td>+1.9%</td>
<td>SPY</td>
</tr>
<tr>
<td>2010</td>
<td>+21.9%</td>
<td>+15.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2009</td>
<td>+2.2%</td>
<td>+26.4%</td>
<td>SPY</td>
</tr>
<tr>
<td>2008</td>
<td>-32.1%</td>
<td>-36.8%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2007</td>
<td>+29.2%</td>
<td>+5.1%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2006</td>
<td>+24.9%</td>
<td>+15.9%</td>
<td>Buffett</td>
</tr>
<tr>
<td>2005</td>
<td>-.02%</td>
<td>+4.8%</td>
<td>SPY</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">The chart shows which stock performed better in the right-hand column.</figcaption></figure>
You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/25/01/42798998/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
<h3 class="wp-block-heading">Key Points: Buffett Vs. SPY</h3>
Berkshire Hathaway beat the S&amp;P 500 in 2024, but significantly underperformed in 2023.
The last down year for the S&amp;P 500 came in 2022 with the SPY down 17.5% for the year. For Berkshire Hathaway, the last down year was in 2015, with a 12.1% decline.
Over the last 20 years, the best return for the SPY was +32.3% in 2013, just outperforming Berkshire Hathaway at +32.2% in the same year.
A look at the worst year also sees SPY win with a 36.8% decline in 2008 compared to a 32.1% decline for Berkshire Hathaway in the same year.
Overall, in the last 20 years, Buffett has won the head-to-head battle 11 times with SPY winning nine times. 
Taking the average return of the last 20 years, Berkshire Hathaway leads at 12.1% to 11.5%.
More importantly, the 20-year return is +669% for Berkshire Hathaway compared to a 20-year return of +621.2% for SPY, adjusted for dividends.
When it comes to investing in the SPY vs. Berkshire Hathaway, the Oracle of Omaha leads the battle across many metrics over the last 20 years, including overall returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/12/42734838/warren-buffetts-chilling-warning-to-employees-lose-a-shred-of-reputation-for-the-firm-and-i-will-be-ruthless">Warren Buffett&#8217;s Chilling Warning To Employees: &#8216;Lose A Shred Of Reputation For The Firm And I Will Be Ruthless&#8217;</a></li>
</ul>
Image: Shutterstock

Education

Management

AAPL

Warren Buffett Beats S&P 500 In 2024, How Oracle Of Omaha's Returns Compare Over Past 20 Years

Ulta Beauty Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares are trading higher in Monday&#8217;s after-hours session after the company announced a CEO transition and <a href="https://www.benzinga.com/pressreleases/25/01/b42830392/ulta-beauty-announces-ceo-transition">updated its near-term outlook</a>.
What Happened: After the market close on Monday, Ulta announced that Dave Kimbell will retire as CEO and step down from the company&#8217;s board, effective immediately.
President and COO Kecia Steelman will succeed Kimbell as president and CEO, effective as of Monday. Steelman will also join the company&#8217;s board. 
&#8220;Kecia is a world-class business executive with deep beauty and retail expertise, an unwavering commitment to effective execution, and a profound passion for our guests and associates. She has been instrumental in developing our recently refreshed strategic framework, and we are confident that she is the right person to lead Ulta Beauty forward,&#8221; said Lorna Nagler, chair of Ulta Beauty&#8217;s board.
See Also: <a href="https://www.benzinga.com/25/01/42825782/bath-body-works-loyalty-program-shines-in-holiday-sales-says-analyst">Bath &amp; Body Works Undervalued: Goldman Sachs Sees Upside Amid Strong Candle Day Performance</a>
In addition to the CEO transition, Ulta updated its fourth-quarter guidance to reflect stronger-than-expected performance during the holiday season. 
The company now expects comparable sales to &#8220;increase modestly.&#8221; Ulta also said it expects operating margin to be above the high-end of the company&#8217;s previous expected range of&nbsp;11.6%&nbsp;to&nbsp;12.4% of sales. 
Ulta is scheduled to report fourth-quarter financial results on March 13. Analysts currently expect the company to report earnings of $6.73 per share and revenue of $3.4 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;I am confident the strategic priorities we shared last fall will enable us to capture greater market share in beauty and wellness and deliver long-term profitable growth, and I am excited to lead our outstanding teams as we unlock even greater advantages of our operating model, drive best-in-class execution, and position Ulta Beauty for our next chapter of growth as the beauty destination for a lifetime,&#8221; Steelman said. 
ULTA Price Action: <a href="http://benzinga.com/quote/ulta">Ulta Beauty shares</a> were up 2.48% after hours, trading at $442 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

ULTA

Ulta Beauty Stock Is Rising After Hours: Here's Why

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 2.69% on an annualized basis producing an average annual return of 14.37%. Currently, Graphic Packaging Holding has a market capitalization of $7.94 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 15 years ago, it would be worth $7,385.47 today based on a price of $26.44 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736199908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=Stoke+Therapeutics%2C+Inc.&amp;index=1&amp;md5=454f1331ad469e0bb2ff820d8c29374c">Stoke Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that its management team will host a webcast and conference call for investors and analysts to discuss successful alignment with global regulatory agencies related to a Phase 3 study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome.
The webcast will be conducted Tuesday, January 7, 2025 at 8:00am Eastern Time and can be accessed from the Investors &amp; News section of Stoke's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestor.stoketherapeutics.com%2F&amp;index=2&amp;md5=0cb1b30b6a3643c6103e41277dc36c53">https://investor.stoketherapeutics.com/</a>. Research analysts who plan to join the call and participate in the Q&amp;A session may register <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBIfb7a43c079834c3cb6a0813f54c1059e&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=3&amp;md5=7af8fd1c74d79d04b91cc2894bac615b">here</a> to receive the dial-in details and a unique PIN. For all others, the listen-only webcast can be accessed by clicking <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fmj8c7ajk&amp;esheet=54173319&amp;newsitemid=20250106021231&amp;lan=en-US&amp;anchor=here&amp;index=4&amp;md5=8eeec19293664ff83d3ffc6172d6dc34">here</a>. A replay of the webcast will be archived and available for at least 90 days following the event.

Biotech

Events

STOK

Stoke Therapeutics To Host Webcast To Discuss Successful Global Regulatory Alignment For A Phase 3 Study Of Zorevunersen As Potentially The First Disease Modifying Medicine For Dravet Syndrome On January 7, 2025 At 8:00am Eastern Time

Equus Appoints Fraser Atkinson As Chairman

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
N2OFF (NASDAQ:<a href="https://investorplace.com/stock-quotes/nito-stock-quote/">NITO</a>) just reported results for the second quarter of 2024.<ul><li>N2OFF reported earnings per share of -23 cents.</li><li>The company reported revenue of $16,546.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nito-stock-earnings-n2off-for-q2-of-2024/">NITO Stock Earnings: N2OFF Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NITO Stock Earnings: N2OFF Reported Results for Q2 2024

N2OFF to pursue food waste carbon credit verra VM00046 methodology

N2OFF (NITO) just unveiled an announcement. N2OFF, Inc., a Nevada corporation, announced the approval for its first PV Solar Project with Solterra ...

N2OFF Announces First PV Solar Project in Germany

N2OFF ( ($NITO) ) has issued an announcement. N2OFF Inc., a clean tech company, along with its partner Solterra, announced the potential for increa...

N2OFF and Solterra's Joint Venture Eyes Expansion

The latest announcement is out from N2OFF ( ($NITO) ). N2OFF, Inc. has expanded its stakeholder base by issuing a significant number of shares, all...

N2OFF Expands Stakeholder Base and Rewards Key Figures

N2OFF ( ($NITO) ) has issued an announcement. N2OFF, a clean tech and agri-tech solutions company, has announced strategic initiatives to boost sha...

N2OFF's Strategic Moves to Enhance Market Position and Value

N2OFF (NITO) announces progress in its collaborative solar photovoltaic project in Melz, Germany, developed by Solterra Renewable Energy. On Decemb...

N2OFF announces JV with Soltera obtained an approval in Meltz Germany

N2OFF (NITO) has signed a binding LOI with Solterra subsidiary, Soltera Brand Services Italy. According to the terms of the LOI the Projects will i...

N2OFF, Solterra Brand Services Italy execute LOI for battery storage projects

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – N2OFF (NITO) up 96% after signing a binding letter...

Morning Movers: U.S. Steel falls after President Biden blocks Nippon deal

N2OFF stock is taking off on Friday after the company signed a binding Letter of Intent with Solterra to develop two battery storage systems.

N2OFF Stock Rockets on Solterra Energy Storage Agreement

CTSO

ENPH

NITO

TAYD

Press Releases

N2OFF INC. to Pursue Food Waste Carbon Credit Verra VM00046 Methodology

N2OFF Inc Joins the EU PV Market: Investing in 111 MW Project in Germany

N2OFF Inc. Solar PV JV Secures Approval to Connect First PV Solar Project in Germany to the Power Grid of a Regional Energy Provider

N2OFF Inc. and Solterra Announce Potential to Increase Capacity in Solar PV Joint Venture Project

N2OFF, Inc: Solterra Advances JV Solar PV Project Following Key Zoning Submission in Melz, Germany

N2OFF Inc. and Solterra Unlock New Potential for Capacity Expansion in Solar PV Project

N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value

N2OFF Announces Letter of Intent with Ethiopian Federal Agency to Mandate Large-Scale Farmers to Utilize Save Foods' Eco-Friendly Solutions

N2OFF, Inc. Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany

N2OFF and Solterra Brand Services Italy executed a binding LOI to Develop Two 98MWp Battery Storage Projects in Sicily

American Vanguard Corporation Common Stock ($0.10 Par Value)

American Vanguard

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions

CF Industries Holdings, Inc. Common Stock

CF Industries Holdings

Corteva

Enlightify

Brazil Potash

Intrepid Potash

Mosaic

Scotts Miracle-Gro Company (The) Common Stock

Scotts Miracle Gro

CVR Partners, LP Common Units representing Limited Partner Interests

Comments

N2OFF

N2OFF (NITO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO